These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 2310930)
21. Adjuvant topical chemotherapy versus immunotherapy in primary superficial transitional cell carcinoma of the bladder. Flamm J; Bucher A Br J Urol; 1991 Jan; 67(1):70-3. PubMed ID: 1993279 [TBL] [Abstract][Full Text] [Related]
22. [Effect of pathologic changes in the urinary epithelium on the absorption of ethoglucide (Epodyl) from the bladder]. Lunglmayr G; Kratzik C; Mattausch M Wien Klin Wochenschr; 1984 Mar; 96(5):182-5. PubMed ID: 6730516 [TBL] [Abstract][Full Text] [Related]
23. Complications of intravesical chemotherapy. Thrasher JB; Crawford ED Urol Clin North Am; 1992 Aug; 19(3):529-39. PubMed ID: 1636237 [TBL] [Abstract][Full Text] [Related]
24. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Soloway MS; Jordan AM; Murphy WM Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268 [TBL] [Abstract][Full Text] [Related]
25. Intravesical and systemic chemotherapy of murine bladder cancer. Soloway MS Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041 [No Abstract] [Full Text] [Related]
26. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study]. Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408 [TBL] [Abstract][Full Text] [Related]
27. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery. Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989 [TBL] [Abstract][Full Text] [Related]
31. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315 [TBL] [Abstract][Full Text] [Related]
32. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080 [TBL] [Abstract][Full Text] [Related]
33. Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity. Groos E; Walker L; Masters JR Cancer; 1986 Sep; 58(6):1199-203. PubMed ID: 3091241 [TBL] [Abstract][Full Text] [Related]
34. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. Walther MM; Figg WD; Linehan WM World J Urol; 1996; 14 Suppl 1():S8-11. PubMed ID: 8738403 [TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach. Schulze M; Stotz N; Rassweiler J J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695 [TBL] [Abstract][Full Text] [Related]
36. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder. Bazarbashi S; Soudy H; Abdelsalam M; Al-Jubran A; Akhtar S; Memon M; Aslam M; Kattan S; Shoukri M BJU Int; 2011 Oct; 108(7):1115-8. PubMed ID: 21332904 [TBL] [Abstract][Full Text] [Related]
37. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547 [TBL] [Abstract][Full Text] [Related]
38. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. Manyak MJ; Ogan K J Endourol; 2003 Oct; 17(8):633-9. PubMed ID: 14622483 [TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra. Taylor JH; Davis J; Schellhammer P Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711 [TBL] [Abstract][Full Text] [Related]
40. Intravesical immunotherapy for superficial bladder cancer. Said MT; Abomelha MS; Orkubi SA Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]